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Breast cancer has an unpredictable course, can be fatal, and many breast cancer treatments and 
prevention strategies are unpleasant and have aversive side effects. Anxiety is a normal reaction 
to a breast cancer diagnosis and may promote adaptive responses to new demands. However, 
anxiety can also have negative psychological and physiological consequences. Past research has 
suggested that trait anxiety may be an important determinant of psychological adjustment as well 
as physiological disease outcomes. The specific effects of trait anxiety on the course of 
psychological functioning during the initial period of adjustment to disease and on disease course 
following diagnosis are not well understood. The primary aim of this study was to evaluate the 
course and influence of trait and acute anxiety in patients diagnosed with breast cancer. This 
study included 58 women with a new diagnosis of breast cancer. Anxiety measures, psychosocial 
distress measures, and salivary cortisol measurements were collected at diagnosis, and 3 and 6 
months post-diagnosis. Overall, anxiety at diagnosis was related to poorer psychosocial 
outcomes during the first six months following a diagnosis of breast cancer. Specifically, trait 
anxiety was more predictive of long-term distress than was state anxiety.
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I.  INTRODUCTION 
 
 
 
Among American women, there is approximately a 13% lifetime risk of developing breast cancer 
and a 3.3% risk of dying from the disease. In 2004, it is expected that over 217,000 new cases of 
invasive breast cancer and 55,700 new cases of in situ breast cancer will be diagnosed (American 
Cancer Society, 2004). Breast cancer has an unpredictable course, can be fatal, and many 
treatments and prevention strategies have aversive side effects. Anxiety is a normal reaction to a 
breast cancer diagnosis and may promote adaptive responses to new demands. However, anxiety 
can also have negative psychological and physiological consequences.  
The prevalence and symptoms of anxiety have been broadly investigated in breast cancer 
prevention, early detection and diagnosis, and treatment (McKenna, Zevon, Corn, & Rounds, 
1999; Kreitler, Kreitler, Chaitchik, Shaked, & Shaked, 1997). The importance of recognizing 
stress and anxiety in this population has been documented (Slaughter et al., 2000; Andrykowski, 
Cordova, McGrath, Sloan, & Kenady, 2000). Still, the course and negative sequelae of specific 
anxiety characteristics in this population are poorly understood.  Recent research has suggested 
that psychophysiological aspects of anxiety can interact with physiological aspects of breast 
cancer in potentially important ways (Cameron, Leventhal, Love, & Patrick-Miller, 2002). 
Specifically, trait anxiety has been related to physiological disease characteristics.  
Although stress and anxiety should be expected to wax and wane as one’s disease or 
treatment outlook changes, trait anxiety may be an important determinant of psychological 
adjustment as well as physiological disease outcomes. This study investigated the impact of trait 
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 anxiety in patients with a new diagnosis of breast cancer by following patients closely during the 
first six months after diagnosis. The primary aim of this study was the evaluation of the course 
and influence of trait and acute anxiety in patients diagnosed with breast cancer. Secondly, this 
study aimed to examine of the course of psychological distress and quality of life in this 
population and to examine the differential influence of trait and acute anxiety on these factors.  
Lastly, this study aimed to examine the relationship between anxiety and physiological markers 
of stress in patients with breast cancer.  
A. Background 
 
The presence of stress has been well identified in patients with cancer (Mettler & Mettler, 
1947; Skarstein, Aass, Fossa, Skovlund, & Dahl, 2000). Generally, stress can be expected with 
any life change and at times has been shown to be adaptive and beneficial, motivating people to 
make difficult lifestyle changes (Kreitler et al., 1997; McCaul, Schroeder, & Reed, 1996). Stress 
in patients with cancer may be acute and dissipate as the situation becomes more normative 
(Epping-Jordan et al., 1999; Irvine, Brown, Crooks, Roberts, and Browne, 1991), however, when 
stress does not dissipate, there is an increased risk for a chronic and interfering psychological and 
physiological responses (e.g., Brabander & Gerits, 1999).  
Physiological and psychological stress and the interplay between the body and mind have 
long piqued the interest of scientific minds. Walter Cannon, a physiologist, was the first to 
describe the body's reaction to stress in the early part of the twentieth century (Greenberg, 1990). 
Cannon described the "fight-or-flight" response as the way the body prepares itself when 
confronted with a threat. It is the process that determines whether an organism will stay and 
“fight” the threat or “flight” and work to avoid the threat. During the same time period, Hans 
Selye, the “father of stress”, worked toward an understanding of the body and mind interaction. 
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 Selye believed that stress was a shared component in all illnesses. He defined stress as the 
nonspecific response of the body to environmental demands. He examined stress and its effects 
on the physiological systems. He conceptualized chronic stress as “exhausting” to the body and 
causing compromised immune system functioning. Later, Lazarus and Folkman (1984) 
introduced and proposed specific psychological appraisal components involved in the 
physiological stress response. More recently, stress has been conceptualized as an emotional 
experience usually accompanied by physiological arousal that results from appraisal of 
information about a stressor and an individual’s perceived ability to deal with it. The emotional 
and physiological reaction experienced either motivates one to change or forces one to 
accommodate to or reduce the effects of the stressor by creating safety from it (Craig, Brown, & 
Baum, 1995).  
Research has suggested several ways in which stress may negatively affect physiological 
activity in individuals with disease (Lovallo, 1997; Cohen, Kessler, & Gordon, 1995). Pathways 
that have been suggested by which stress affects disease progression include the influence of 
stress on hormone levels and immune responses (Luecken & Compass, 2002; Cohen et al., 
1995). Specifically, stress in women with breast cancer has been shown to be associated with 
natural killer cell activity, T and B cell activity, and lymphocyte counts (Andersen, Kiecolt-
Glaser, & Glaser, 1994; Tjemsland, Soreide, Matre, & Malt, 1997). Data from laboratory and 
psychosocial interventions studies aimed at reducing stress have suggested that stress levels may 
even be associated with the progression of disease in patients with cancer (Forlenza, Latimer, & 
Baum, 2000; Spiegel et al. 1989).  
Situations that are perceived as threatening (e.g., disease diagnosis) can cause stress and 
may trigger anxiety in the individual. Barlow (2000) characterizes anxiety as being a state of 
3 
 helplessness, because of perceived inability to predict, control, or obtain desired results or 
outcomes in upcoming personally salient situations or contexts. The prolonged or chronic 
manifestation of anxiety is dependent on the nature of the stress, the coping ability of the 
individual, and the social context of the stressor. Anxiety can become problematic when it is so 
intense that it diminishes efforts at coping and attention is solely focused on reducing distress 
and fear. This reaction can potentially affect appraisal of future stressors and change the 
experience of stress in routine events (Craig et al., 1995).  
Non-chronic anxiety has been defined as state (or acute) anxiety, which can be descried as 
a temporal cross section in the emotional stream of one’s life, consisting of subjective feelings of 
tension, apprehension, nervousness, worry, and activation of the autonomic nervous system. 
Conversely, trait anxiety refers to individual differences in the stable and enduring tendency to 
perceive a wide range of situations as dangerous or threatening, and to respond with more 
frequent and intense elevations in state anxiety (Spielberger, Gorsuch, & Lushene, 1970). Stress 
has been measured in the context of event related anxiety, anxiety disorders, symptoms, and 
characteristics, yet there still remains little consensus as to when and how stress for the patient 
with cancer moves from a normal and expected stress reaction to one with negative 
consequences. 
 
1. Anxiety and Breast Cancer. Elevated levels of anxiety can potentially cause a wide variety of 
psychological and physiological problems for patients with breast cancer. Anxiety has been 
associated with an increase in pain, interference with sleep, and increased negative response to 
chemotherapy treatment. Anxiety in has also been associated with an increase in somatic 
symptoms causing subsequent early termination of potentially curative treatments (Love, 
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 Leventhal, Easterling, & Nerenz, 1989). Additionally, anxiety has been associated with 
decreased quality of life in patients with cancer as well as their family members.   
Women with breast cancer that have elevated acute anxiety may experience more intrusive 
thoughts and less optimism than less anxious women (Epping-Jordan et al., 1999), both of which 
have been associated with negative psychological and physiological effects (Scheier, Carver, & 
Bridges, 1994; Baum, Cohen, & Hall, 1993).  Intrusive thoughts have also been associated with a 
higher rate of health complaints, depression, sleep problems, and an elevated risk for distress as 
long as two years post breast cancer diagnosis (Bleiker, Pouwer, van der Ploeg, Leer, & Ader, 
2000). 
Intrusive thoughts are a hallmark characteristic of anxiety and Posttraumatic Stress 
Disorder (PTSD), which has been studied as a response to a diagnosis of breast cancer. Several 
clinical studies have reported that some patients with cancer and their family members exhibit 
PTSD-like symptoms following cancer diagnosis and treatment. Those expressing a more 
emotionally reactive and anxious personality type have exhibited a heightened risk of developing 
significant PTSD symptoms in response to cancer diagnosis and treatment (Smith, Redd, Peyser, 
& Vogl, 1999). These risk factors suggest that pre-existing chronic anxiety may increase distress 
and the likelihood of PTSD symptoms in patients with cancer.   
Research on anxiety in patients with cancer often has assumed that it is high levels of state 
anxiety that are problematic in adjustment to disease. This is evident in the fact that most studies 
of anxiety symptoms in cancer populations are based on single assessments, are usually 
associated with an event or procedure and often focus on the diagnosis of an anxiety disorder 
(e.g., Slaughter et al., 2000; Smith, et al., 1999). These approaches imply transient increases in 
anxiety. However, research provides some evidence for a differential experience for patients with 
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 cancer that have high levels of trait anxiety. High levels of trait anxiety may uniquely influence 
psychological and physiological disease mechanisms (Cameron, Leventhal, & Love, 1998; 
Cameron et al., 2002). Although chronically elevated levels of anxiety may not reflect clinical 
episodes, distress remains during the course of everyday activity and contributes to hyperactive 
endocrine responses (Sullivan, Kent, & Copeland, 2000).  
 
2. Trait Anxiety. In women with breast cancer, trait anxiety was shown to be inversely related to 
feelings of well-being (Kaczorowski, 1989), and cause increased and persistent psychological 
and physiological distress related to chemotherapy treatment (Jacobsen, Bovbjerg, & Redd, 
1993). Patients with cancer who have high levels of trait anxiety have different patterns of 
immune system change and have an increased capacity for developing conditioned nausea and 
vomiting in response to chemotherapy treatment (Fredrikson, Furst, Lekander, Rotstein, & 
Bloomgren, 1993). Additionally, the interactions between trait anxiety and the endocrine system 
have been reported to delay recovery and increase pain from surgery (Mathews & Ridgeway, 
1981).  
High levels of trait anxiety have been commonly described as a catalyst for over-reporting 
of symptom experience because of hypervigilance to external and internal environments for cues 
of danger or threat (Gray, 1982; Watson & Clark, 1984). Due to the necessity of success in 
cancer treatments, accurate symptom reporting and accurate conceptualizing of reported 
symptoms is crucial. Although over-reporting has been associated with patients who have high 
levels of trait anxiety, there is no clear evidence that this increase in symptom reporting is an 
inaccurate report of somatic activity (Cameron et al., 1998).  
Cameron and colleagues (1998) examined the relationship between trait anxiety and 
physiological symptom reporting in a group of women with breast cancer that were participating 
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 in a placebo-controlled trial of tamoxifen. They were interested in the influence of trait anxiety 
on the symptomatic side effects induced by tamoxifen. High levels of trait anxiety were 
associated with greater and more rapid increases in symptom reporting, however, high symptom 
reports were of symptoms expected to emerge from tamoxifen treatment and could be attributed 
to actual experience and not to over-reporting. These findings suggested that trait anxiety may be 
associated with a differential symptom experience.  
Further investigations again found that although patients with high trait anxiety did report 
more symptoms, when directly tested there remained no evidence to suggest that patients with 
high trait anxiety were less accurate in their symptom report. Rather, it was found that patients 
were reporting an increased number of vague symptoms of treatment (tiredness, mood swings, 
fatigue), but that their initial and retrospective reports of concrete symptoms (hair loss, vomiting, 
mouth sores) were neither increased nor inconsistent. Trait anxiety was consistently and 
positively related to vague symptom report but not to concrete symptom report. This increased 
report and symptom experience, further suggested trait anxiety as a marker of endocrine 
reactivity (Rabin, Ward, Leventhal, & Schmitz, 2001). This system may already be being taxed 
by a chronically alert stress system in patients with high trait anxiety, and the interaction of the 
chemotherapy regimen may actually produce a greater endocrine symptom response.  
These results suggested that trait anxiety may also affect the pharmokokinetics of 
tamoxifen and may contribute to differential outcomes of tamoxifen therapy. This is important as 
the presence of anxiety may alter the amount of circulating drug, reduce overall effectiveness of 
estrogen blockade, and affect how bothersome side effects may be. Cameron and colleagues 
(2002) hypothesized that trait anxiety may be a marker for a physiological substrate moderating 
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 the estrogen-agonist effects of tamoxifen on lumbar spine bone mineral density (BMD) and 
levels of sex hormone binding globulin (SHBG).  
They found that tamoxifen produced greater preservation of BMD of the lumbar spine in 
trait anxious women. Trait anxiety was also associated with a suppression of tamoxifen-induced 
increases in SHBG. This finding is consistent with the physiology of chronic anxiety that when 
the body’s stress system is alerted other systems, such as the reproductive system which is 
import in the production of SHBG, shut down. Although tamoxifen significantly increased 
SHBG levels regardless of anxiety level, women with high trait anxiety exhibited smaller mean 
changes in SHBG. These data suggested that trait anxiety might be an indicator of a 
physiological substrate that affects estrogen-agonist effect of tamoxifen and provided evidence 
regarding the physiological mechanisms underlying trait anxiety. Neuroendocrine processes 
associated with high trait anxiety appear to interact with estrogenic agents in ways that influence 
physiological outcomes. 
Physiological theories of persistent (or trait-like) anxiety suggest that there is a chronic 
alertness of the “stress system” (Barlow, 2000). When activated this system produces several 
hormones including catecholamines and cortisol, that are known to suppress immune function, 
and to have a range of other effects. The endocrine system is thought to be influenced by trait 
anxiety (Sullivan et al., 2000) and it has been hypothesized that the endocrine system may 
participate in growth of human breast cancer (Henderson, 1995). The effects of chronic stress 
have also been shown to decrease the activity of natural killer cells and other anti-tumor effectors 
(Murphy, Lawrence, & Lenhard, 1995). The brain’s stress response system, specifically the 
processes implicated in trait anxiety, may interact in important ways with systems that have been 
implicated in the initiation or progression of breast cancer and the general disease process. 
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3. Anxiety and Cortisol. Cortisol is a hormone secreted by the hypothalamic-pituitary-adrenal 
(HPA) axis, which participates in a number of important functions in humans. The HPA axis 
affects several physiological response systems, including the immune system (Lovallo, 1997). 
Cortisol reduction is thought to represent changes in the HPA axis. The HPA system and cortisol 
are known to play a key role in the adaptation of the body to both physical and psychological 
stress (Van der Pompe, Antoni, & Heijnen, 1996). Increases in cortisol levels are typical 
biochemical signs of stress (Bohnen, Nicolson, Sulon, & Jolles, 1991). Cortisol has been used as 
a measure of anxiety levels and also as a marker of immune functioning (Cohen et al., 1995) and 
evidence from animal paradigms has suggested the involvement of cortisol on immune cell 
distribution in response to acute stress (Ottaway & Husband, 1992).High trait anxiety has been 
associated with significant elevations in cortisol levels in healthy subjects (van Eck, Berkhof, 
Nicolson, & Sulon, 1996), and elevated levels of plasma and urinary cortisol have been 
associated with increased levels of daily stress and increased levels of perceived stress (Brantley, 
Dietz, McKnight, Jones, & Tulley, 1988; Pruessner, Hellhammer, & Kirschbaum, 1999).  
Alterations in HPA axis function have been reported in women with breast cancer 
indicated by flattening of the circadian rhythm of cortisol secretion and elevated plasma cortisol 
levels (Cruess et al., 2000). Such differences may be due to disease and treatment effects on the 
endocrine system or to psychological stressors associated with a cancer diagnosis and treatment. 
Additionally, the progression of breast cancer has been associated with abnormal HPA responses 
(Van der Pompe et al., 1996). These data suggest that cortisol levels may be related to disease 
status and that breast cancer may be associated with a hyperactive adrenal gland resulting in 
chronically increased cortisol levels.  
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 B. Summary, Goals, and Hypotheses 
 
The critical implication of these findings is the suggestion that trait anxiety may affect overall 
well-being as well as the course of disease in patients with breast cancer. Despite growing 
evidence of the importance of such variables, published reports focusing on the psychological 
correlates and physiological distress associated with trait anxiety in this medical population are 
limited. In clinical decision making it is likely that there is little differentiation made between 
trait and state anxiety. Trait anxiety may often be overlooked because it does not meet 
diagnostic criteria for an anxiety disorder and may not be differentiated from state anxiety 
when more acute measures of anxiety are used to assess distress. A thorough and accurate 
understanding of the psychological and physiological distress variables associated with trait 
anxiety will assist to inform treatment choices, adjunct psychological interventions strategies, 
and other clinical decision-making in patients with breast cancer. This research will attempt to 
provide a better understanding of these factors.  
It was hypothesized that women with breast cancer would report higher levels of acute 
anxiety at diagnosis than at 3 or 6 months post-diagnosis, but trait anxiety would not fluctuate 
over time. It was also expected that trait anxiety at diagnosis would more strongly predict acute 
symptoms of anxiety at 3 and 6 months post-diagnosis than would acute anxiety at diagnosis. It 
was expected that measures of psychosocial distress (e.g., general stress, depression, general and 
medical worry, quality of life, and symptom reporting) would be increased at diagnosis 
compared to 3 and 6 months post-diagnosis, with trait anxiety at diagnosis accounting for more 
of the variance in psychosocial distress over time than would state anxiety at diagnosis. Quality 
of life directly influenced by physical functioning was expected to fluctuate during this time 
period due to the course of cancer treatments. Lastly, it was expected that increased levels of 
10 
 physiological distress at diagnosis as measured by salivary cortisol levels would be related to 
self-report measures of anxiety at each time point and that salivary cortisol levels at diagnosis 
would account for a significant amount of the variance in self-reported anxiety at diagnosis and 3 
and 6 months after diagnosis.   
11 
  
 
 
II. METHODS 
 
 
 
 
In designing this study, careful attention was paid to difficulties in accrual of subjects, limiting 
subject response burden, and minimizing participant attrition. All eligible patients who were 
willing to consider participation met individually with the primary investigator who explained 
the study and obtained informed consent. Sixty-five participants were recruited in an eleven-
month period and each subject was followed for six months at three month intervals beginning at 
baseline, time 1, (not more than four weeks post-diagnosis). 
A. Participants 
 
 
The 65 women with newly diagnosed primary stage breast cancer were recruited and provided 
informed consent for this study. Fifty-eight women completed all the study materials at Time 1. 
Participants ranged in age from 35-78 with a mean age of 56 (SD = 10). Participants were 
predominantly Caucasian (98%); reflecting the population seen at Magee Women’s Hospital. Of 
these women, 60% were married, 12% were single, 19% were separated or divorced, and 9% 
were widowed. Sixty-five percent reported having a yearly family income of greater than 
$30,000 and 83% reported having some educational training beyond high school. About half 
reported working full or part time (53%), and 25% reported being retired, 15% were 
homemakers,  and 7% were unemployed or on disability. Twenty-seven percent of this sample 
reported having at least one child under 18 living at home. The participants reported religious 
preferences were Catholic (42%), Protestant (48%), Orthodox (2%), and no affiliation (8%).  
12 
  
1. Cancer Information. Thirteen percent of women in this study were diagnosed with in situ 
(stage zero) breast cancer, 46% with stage one breast cancer, 30% with stage two breast cancer, 
and 11% with stage three breast cancer. Lumpectomy/segmental mastectomies were performed 
on 78% of these women, 15% had a total mastectomy, 3.5% had a modified radical mastectomy, 
and 3.5% had a bilateral mastectomy. Three months post-diagnosis, 69% of participants were 
receiving chemotherapy and 32% were receiving radiation treatment. Among participants, a total 
of 39% reported having a positive family history of breast cancer diagnosis in their mother 
(14%), a sister (9%), an aunt (26%), and/or child (2%). Regarding deaths due to breast cancer, 
22% reported having a mother, grandmother, aunt, or sister die as a result of breast cancer.   
 
2. Medical and Health Information. Nineteen percent of these women reported they were pre-
menopausal, 15% reported they were peri-menopausal, 61% reported they were post-
menopausal, and 5% did not report this information. Of the 58 participants, 83% reported no 
current psychological treatment, 16% were currently taking medication for psychological 
reasons, and 1% reported current psychological therapy. Reasons listed for psychological 
treatment were anxiety, depression, or relationship difficulties. Ten percent of participants 
reported being current smokers, 42% reported currently using alcohol at least occasionally, and 
53% reported daily caffeine use. Regarding exercise, 10% reported never exercising, 44% 
reported that they exercised 1-2 times per week, 36% reported exercising 3-4 times per week, 
and 10% reported exercising 5 or more times per week. 
 
3. Exclusion Criteria. Participants were eligible if they were over the age of 18, if this was their 
first diagnosis of cancer, if they had suspected early clinical stage (0,1,2) breast cancer, if they 
were able to read and write English, and if they were capable of informed consent. Individuals 
13 
 were excluded if they exhibited a predominant medical condition other than the new breast 
cancer diagnosis, if there was behavioral evidence of significant psychiatric illness, psychosis, or 
organic brain syndrome, or if there was evidence of active suicidal ideation. 
 
B. Procedures 
 
 
All potential participants had been informed of their new diagnosis within the previous four 
weeks and had not yet had surgery or begun their cancer treatment regimen. Medical staff 
identified potential participants. If patients agreed to speak with an investigator, the patient was 
then informed of the purpose and requirements of this study and if willing to participate, patients 
were provided with an informed consent. After signing the informed consent, patients were given 
a packet of questionnaires and other study materials. Packets included a diary to record details 
for the cortisol measurements, materials to collect cortisol samples, and, if desired by the 
participant, a beeper was included to remind patients when to do their cortisol collections. Each 
set of questionnaires required approximately 45 minutes to complete.  
Procedures for collecting saliva samples for measuring cortisol were explained. Each 
packet also contained written procedural instruction as well as specific instructions about the use 
of salivettes and recording diaries. The diaries served to remind participants of sampling times 
and to record and verify actual sampling times. Participants were asked to complete salivary 
cortisol samples for one day within one hour of waking, at 11 a.m., 3 p.m., 6 p.m., and 9 p.m. 
Patients were contacted at their beeper at each collection time to prompt them to complete their 
cortisol sampling if they desired. Participants were requested to complete all study requirements 
within four days and to return all study forms in a provided postage paid self-addressed 
envelope.  
14 
 The second and third packets were sent to participants that completed the previous time 
point with a postage-paid return addressed envelope. Patients were contacted by phone two 
weeks prior to the mailing of each packet and reminded to expect questionnaires and saliva 
cortisol equipment by mail and to complete and return questionnaires and cortisol samples within 
four days after receiving them. Participants received $20.00 upon the return of each packet. 
Information on disease characteristics, treatment information, patient blood pressure reading, and 
height and weight measurements was collected from the patient’s medical chart. 
 
C. Measures 
 
 
1. Control variables. All participants completed a sociodemographic questionnaire designed 
specifically for this study at all time points. Variables assessed to describe patient demographic 
characteristics were age, marital status, education, income, and number of children at home. The 
use of psychiatric medication, family cancer history, and health behavior information was 
obtained. Disease characteristics were determined through review of medical charts at Magee 
Women’s Hospital. These variables were measured for descriptive purposes, as well as to allow 
for examination of potential alternative explanations for findings. 
 
2. Predictor and Outcome Variables. Each variable was measured at all three time points in the 
study. Anxiety was measured using the State-Trait Anxiety Inventory (STAI; Spielberger et al., 
1970). The STAI consists of two scales of items, with each scale comprised of 20 questions (40 
total). One scale specifically measures state anxiety and the other scale measures trait anxiety. 
Superior internal consistency is shown with the alpha coefficients for both scales being 
uniformly high with median coefficients of 0.93 for the state anxiety scale and 0.90 for the trait 
15 
 anxiety scale. Test-retest stability is also relatively high for the trait anxiety scale with median 
stability coefficients as high as 0.77. Test-retest stability is relatively low for the state anxiety 
scale, as would be expected, because of its purpose to assess transitory changes in anxiety 
(Spielberger, Sydeman, Owen, & Marsh, 1999).  
The Depression Anxiety Stress Scale (DASS; Lovibond & Lovibond, 1995) was used to 
measure depression and distress. The anxiety scale (DASS-A) of this measurement was designed 
to eliminate symptoms of anxiety that could potentially overlap with depression and is 
conceptualized as a “pure” measure of anxiety. The DASS has 42 questions answered on a scale 
of 0 to 3. Analyses indicate that the DASS is a reliable and valid measure of anxiety, depression, 
and stress. The DASS’s three-factor structure discriminates between anxiety and depression 
better than other commonly used measures (Brown, Chorpita, Korotitsch, & Barlow, 1997). 
Worry was measured with the Worry Domains Questionnaire (WDQ; Tallis, Davey, & 
Bond, 1994). It is a widely used instrument that assesses the amount of non-pathological worry 
across five domains of everyday concern: relationships, lack of confidence, aimless future, work, 
and financial issues. Research has demonstrated that the WDQ shows high reliability and 
substantial validity, with good internal consistency (Cronbach’s α  > .90) and with test-retest 
stability across four weeks being 0.85 (Stober & Joormann, 2001). Five questions were added to 
the WDQ that specifically addressed patient’s worry of disease recurrence, apprehensiveness 
about treatment procedures and tests, and disease worry. In this study the alpha levels for these 
five questions were .91, .90, and .84 at each time point respectively. The medical specific 
questions were not added into the total score, but were considered separately in all analyses. 
Quality of life was measured using the Medical Outcomes Study Short Form (MOS; Ware 
& Sherbourne, 1992). Quality of life was used as an outcome variable and was assessed with this 
16 
 brief, comprehensive multi-item instrument measuring eight functional domains relating to 
health. Domains included: limitations in physical activities due to health problems, limitations in 
social activities due to physical or emotional problems, limitations in usual role activities due to 
physical health problems, bodily pain, limitations in usual role activities because of emotional 
problems, vitality, and general health perceptions. The MOS also generated one global score for 
mental health and one for physical health. The MOS measures have acceptable reliability for 
group comparisons across age, gender, ethnicity, education, and disease groups (McHorney, 
Ware, Lu, & Sherbourne, 1994). Responses were scored on a 5 point likert scale and transformed 
to a 0-100 scale. These scores were reversed in this study for consistency among measures so 
that 0 = best health and 100 = poorest health. 
The Symptom Checklist 90, Revised (SCL-90; Derogatis, 1977) was used as an outcome 
variable to provide a global index of symptom reporting as well as intensity of distress scores for 
nine clinical problem dimensions. The subscales include somatic complaints, interpersonal 
problems, depression, anxiety, hostility, paranoia, phobia, and psychotic symptoms. Ninety items 
are rated on a five-point Likert scale of distress ranging from 0 = not at all to 5 = extremely. 
Internal consistency for the nine subscale ranges from .78 to .90 and one week test-retest 
reliability ranges between .78 and .90 (Derogatis & Melisaratos, 1983). 
Physiological symptoms of distress were assessed through the measurement of salivary 
cortisol.  Salivary cortisol was used as collected from participants at each assessment time point 
in the study and served as a physiological marker of anxiety. Historically it has been difficult to 
interpret the association of stress and cortisol levels because this measure has traditionally been 
collected with a blood sample. Blood sampling provides a very time limited “snapshot” of 
cortisol levels and some stress may be induced by vein puncture and the medical procedure itself. 
17 
 However, salivary cortisol is collected several times during the day, is less reactive, and has been 
shown to reliably reflect levels of unbound cortisol in the blood and raised levels have been 
found to be associated with stress in normal subjects (Kirschbaum & Hellhammer, 1994).  
Sampling spaced across the waking day was done to allow for the evaluation of the shape 
and periodicity of cortisol production over time, while avoiding typical lunch and dinner hours, 
reducing the potential effects of eating on cortisol levels. Collection of each cortisol sample 
requires very little time or burden; participants chew on a sterilized cotton wedge for 30 seconds, 
place it in a small test tube, and insert this into a salivette cover. The completed samples were 
returned to the medical center within 36 hours and centrifuged and frozen at –70 º C. Assessing 
for adherence to cortisol sampling is difficult, however, there is a normal diurnal curve that is 
expected throughout the day. In this sample, approximately 80% of participants with completed 
samples had results that followed this general pattern. 
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III. DATA ANALYSES AND RESULTS 
 
 
 
Data were analyzed with SPSS version 11.0.1. Initially, the distributions, descriptive statistics 
(see Tables 1-4), and intercorrelations of all variables were examined to determine normality and 
multicollinearity. Additionally, intercorrelations among the various dependent variables were 
examined and any variables that were consistently and highly related to one another were 
combined or analyzed simultaneously as appropriate. In this way, the overall number of 
dependent variables as well as number of comparisons was reduced.  
To correct for non-normal distributions, square-root transformations were used on all of 
the psychosocial self-report measures and logarithmic transformation was used on the cortisol 
variable. Zero-order correlations coefficients between self-reports and background variables 
(age, marital status, income, education, children in the home, psychological medication use), 
health behavior variables (exercise frequency, eating habits, smoking, alcohol use frequency, 
caffeine use frequency), family breast cancer history (mother, aunt, or sibling diagnosis and 
family death due to breast cancer), and medical variables (breast cancer stage, surgery type,  
radiation and chemotherapy treatment for cancer, blood pressure, weight) were examined to 
identify potential covariates. Significant correlations are listed in Tables 5-11. Most of these 
correlations were relatively small, accounting for less than 25% of the variance in any measure 
and the pattern of relationship was consistent with previous research. Based on these 
relationships, variables were used as covariates in analyses as appropriate.  
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 Table 1 
 
Means and Standard Deviations of Self-Report Full Scales for Completers at Each Time 
 
 Diagnosis 
n = 58 
3 Months 
n = 51 
6 Months 
n = 42 
Variable M SD M SD M SD 
Trait Anxiety 36 9.8 36 10 34 9 
State Anxiety 37 14 33 11 30 10 
DASS Anxiety 4.6 6.0 3.3 4.9 2.8 3.8 
DASS Depression 6.0 7.1 5.0 6.5 3.9 5.3 
DASS Stress 9.1 7.2 7.7 8.3 6.7 5.7 
Worry Total 13.3 15.9 13.9 16.4 14.5 16.4 
Worry Medical 10.5 5.8 7.8 5.4 6.9 4.2 
SCL-GSI .49 .44 .48 .48 .41 .40 
MOS Mental Health 30 21 26 21 20 18 
MOS General Health 31 18 35 18 31 16 
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 Table 2 
Means and Standard Deviations of Variables Among Full Completers (n = 42) 
 
 Diagnosis 3 Months 6 Months 
Variable M SD M SD M SD 
Trait Anxiety 36 11 36 10 34 9 
State Anxiety 37 15 33 12 30 10 
DASS Anxiety 4.4 6.1 3.0 4.3 2.8 3.8 
DASS Depression 6.1 7.8 4.6 6.2 3.9 5.3 
DASS Stress 8.9 7.3 6.8 6.3 6.7 5.7 
Worry Total 13.7 16.6 12.8 15.1 14.5 16.4 
Worry Medical 10.3 5.7 7.7 5.1 6.9 4.2 
SCL-GSI .50 .48 .45 .45 .41 .40 
MOS Mental Health 29 21 24 20 20 18 
MOS General Health 31 19 35 18 31 16 
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 Table 3 
Means and Standard Deviations of WDQ Subscales and SCL-90-R Subscales (n = 42) 
 
 Diagnosis 3 Months 6 Months 
Variable M SD M SD M SD 
WDQ Finances 4.07 5.01 3.62 4.40 4.64 5.37 
WDQ Work 2.81 3.32 2.83 3.27 3.17 3.35 
WDQ Aimless Future 2.86 3.85 2.48 3.49 2.81 3.70 
WDQ Lack Confidence 2.69 3.70 2.33 3.33 2.55 3.33 
WDQ Relationship 1.29 3.01 1.55 2.74 1.31 3.00 
SCL Somatic .49 .52 .62 .50 .63 .54 
SCL OCD .79 .67 .63 .58 .61 .53 
SCL Interpersonal .37 .56 .43 .60 .37 .47 
SCL Depression .68 .70 .62 .58 .53 .60 
SCL Anxiety .58 .68 .30 .49 .26 .45 
SCL Hostility .25 .44 .24 .37 .23 .35 
SCL Phobia .11 .34 .13 .32 .10 .30 
SCL Paranoid .28 .35 .26 .45 .23 .36 
SCL Psychotic .34 .41 .22 .34 .19 .31 
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 Table 4 
Means and Standard Deviations of MOS Scales (n = 42) 
 
 Diagnosis 3 Months 6 Months 
Variable M SD M SD M SD 
Physical Functioning 15 21 27 25 26 21 
Physical Role 36 36 68 41 47 37 
Body Pain 23 19 34 26 33 24 
General Health 30 17 35 18 31 16 
Vitality  42 20 53 23 47 20 
Social Functioning 20 20 29 26 22 25 
Emotional Role 37 41 30 42 22 32 
Mental Health 29 21 24 20 20 18 
Health Transitions 97 .84 98 1.0 98 1.1 
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 Table 5 
 
Correlations between background variables and self-report measures (n = 42) 
 Age Marriage Income Psych 
Med 
Exercise Eat 
Habits 
Smoking 
Trait Anxiety        
  Diagnosis .05 -.29 -.12 .45* -.23 .22 .29 
  3 Month -.10 -.23 -.04 .49* -.12 .07 -.28 
  6 Month .01 -.32* -.22 .29 .12 -.08 -.09 
State Anxiety        
  Diagnosis -.21 -.07 -.01 .21 -.17 -.07 -.21 
  3 Month .07 -.13 -.01 .17 -.17 .20    -.31* 
  6 Month .03 -.33* -.16 .11 -.05 .15 -.17 
DASS Anxiety        
  Diagnosis -.17 -.05 -.01 .45** -.37* -.17 .01 
  3 Month -.09 -.24 -.22     .42* -.23 .14 -.10 
  6 Month .01 -.11 -.10 .24 -.24   .42** .06 
DASS Stress        
  Diagnosis -.24 -.24 -.07 .50** .19 -.04 -.05 
  3 Month -.17 -.06 .14     .40* .03 .09 -.08 
  6 Month -.20 -.30 -.15 .23 .08 -.03 .29 
DASS Depression        
  Diagnosis -.29 -.24 -.07 .46** -.19 -.03 -.09 
  3 Month -.30 -.30 .03     .39* -.10 .20 -.20 
Table 5 (continued). 
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  6 Month -.15 -.41** -.26 .20 -.20 -.01 .07 
WDQ Total        
  Diagnosis -.08 -.37* -.20 .35* -.09 .07 -.16 
  3 Month -.07    -.33* -.18 .23 -.19 .16 -.21 
  6 Month -.11  -.44** -.36** .14 -.07 .19 -.03 
WDQ Medical        
  Diagnosis -.31 -.21 .15 .15 .01 .20 -.02 
  3 Month -.32* -.22 .01 .04 .10 .23 .01 
  6 Month -.43** -.33* -.11 .03 -.18 -.02 -.04 
MOS Mental Health        
  Diagnosis -.35* -.06 .12 .36* -.18 .10 -.12 
  3 Month -.26 -.17 -.04 .26 -.25 .25 -.24 
  6 Month -.22 -.19 -.06 .18 .11 .26 -.17 
SCL GSI        
  Diagnosis -.12 -.21 -.07   .48** -.24 -.01 -.18 
  3 Month -.07 -.32* -.15     -.32* -.19 .21 -.22 
  6 Month -.01  -.42** -.35* .20 -.02 .13 -.17 
*p < .05. **p < .01. ***p < .001. 
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 Table 6 
Correlations between medical variables and self-report measures (n = 42) 
 BC Stage Systolic Weight Radiation Chemotherapy 
Trait Anxiety      
  Diagnosis -.30 .30 .27 - - 
  3 Month -.34* .46* .39* -.11 .05 
  6 Month -.40* .29 .28 .23 -.33* 
State Anxiety      
  Diagnosis -.20 .29 .11 - - 
  3 Month -.43** .60** .33* -.06 -.20 
  6 Month -.28 .44* .22 .06 -.22 
DASS Anxiety      
  Diagnosis .05 .10 .03 - - 
  3 Month -.25 .30 .40* -.03 -.03 
  6 Month -.07 .25 .19 -.11 .01 
DASS Stress      
  Diagnosis -.14 .24 .09 - - 
  3 Month -.37* .44* .22 .43** -.10 
  6 Month -.29 .27 .06 .25 -.04 
WDQ Total      
  Diagnosis -.26 -.04 .40** - - 
  3 Month -.18 .26 .35* .02 -.09 
  6 Month -.17 .15 .28 -.12 -.26 
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 Table 6 (continued). 
 
MOS Gen Health      
  Diagnosis -.09 .44* .11 - - 
  3 Month .04 .34 .14 .16 .21 
  6 Month .07 .40* .11 -.06 .19 
MOS Men Health      
  Diagnosis -.08 .10 .08 - - 
  3 Month -.16 .43* .18 -.02 -.09 
  6 Month -.31* .29 .02 -.01 -.22 
*p < .05. **p < .01. ***p < .001. 
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 Table 7 
 
Correlations between background variables and WDQ Subscales (n = 42) 
 Marriage Income Psych Med Stage Chemo Systolic Weight 
Finances        
  Diagnosis -.33* -.26 .12 -.19 - .07 .38* 
  3 Month -.26 -.30 .05 -.10 -.06 .02 .30 
  6 Month -.30 -.40* -.09 -.19 -.17 -.05 .17 
Work        
  Diagnosis -.19 -.07 .41** -.23 - .36 .22 
  3 Month -.13 .03 .25 -.17 .05 .34 .25 
  6 Month -.26 .18 .15 -.07 -.19 .19 .15 
Aimless Future        
  Diagnosis -.28 -.02 .28 -.16 - .14 .33* 
  3 Month -.25 -.06 .20 -.11 .01 .14 .38* 
  6 Month -.42** -.31 .05 -.16 .13 .10 .35* 
Lack Confidence        
  Diagnosis .08 -.33* .46** -.31 - .41* .36* 
  3 Month -.40** -.27 .30 -.34* -.38* .42* .30 
  6 Month -.46** -.35* .30 .26 .26 .42* .27 
Relationship        
  Diagnosis .08 -.31 .31* -.24 - .25 .48** 
  3 Month -.38* -.22 .32* -.11 -.01 .23 .28 
  6 Month -.40** .27 .28 -.16 -.09 .20 .40** 
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 Table 8 
Correlations between background variables and MOS Subscales (n = 42) 
 Age Income Exercise Eating 
Habits 
Alcohol 
Use 
Caffeine 
Use 
Physical Function       
  Diagnosis .52*** -.14 -.30 -.05 -.33* -.05 
  3 Month -.031 -.28 -.24 .12 -.30 .01 
  6 Month .06 -.37* -.32* .01 .52*** -.54*** 
Physical Role       
  Diagnosis -.24 .08 -.05 -.08 -.06 .07 
  3 Month -.19 -.03 -.38* -.02 -.24 -.09 
  6 Month -.06 -.05 -.22 -.02 -.43** -.30* 
Body Pain       
  Diagnosis .14 -.38* -.23 -.09 -.10 .11 
  3 Month -.30 .13 -.20 .14 -.13 .10 
  6 Month -.11 -.31 -.17 .13 -.19 -.38* 
Vitality       
  Diagnosis -.31 .24 -.02 -.07 .12 .03 
  3 Month -.38* -.06 .32* .02 -.03 .06 
  6 Month -.27 .97 -.17 .11 -.15 -.35* 
Social Function       
  Diagnosis -.25 -.21 .03 .05 -.39* .05 
  3 Month -.32* .50 -.21 -.07 -.42** -.08 
Table 8 (continued).  
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  6 Month -.31* -.20 -.21 -.09 -.58*** -.23 
Emotional Role       
  Diagnosis -.31* -.02 .03 .02 .10 .23 
  3 Month .08 -.16 .39* .14 -.20 .20 
  6 Month -.06 -.16 .04 .46** .06 .20 
*p < .05. **p < .01. ***p < .001. 
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 Table 9 
 
Correlations between medical and family breast cancer history variables and MOS Subscales (n 
= 42) 
 Systolic Diastolic Weight Radiation Surgery Aunt 
Breast 
Cancer 
Family 
Breast 
Cancer 
Family 
Death 
Cancer 
Physical 
Function 
        
  Diagnosis .12 .42* .37* - - .26 .19 .32 
  3 Month -.02 -.35 .27 -.18 -.04 .48** .35* .21 
  6 Month -.21 -.43* .21 -.14 .19 .24 .25 .09 
Physical Role         
  Diagnosis .13 -.24 .29 - - .08 -.02 .13 
  3 Month -.05 -.27 -.05 -.16 .34* .15 .04 -.17 
  6 Month -.22 -.20 -.12 -.24 -.18 .01 .06 -.12 
Body Pain         
  Diagnosis .17 -.21 .37* - - .27 .02 .30 
  3 Month -.01 -.49** .22 -.06 -.09 .25 .09 .02 
  6 Month .11 -.38* .10 .01 .18 .06 .07 -.20 
Vitality         
  Diagnosis .19 -.03 .17 - - .04 -.15 -.17 
  3 Month .11 -.24 .07 .17 .16 .01 -.01 -.17 
  6 Month .08 -.32 .01 -.33* .20 -.05 .03 -.36* 
Table 9 (continued). 
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 Social 
Function 
        
  Diagnosis -.04 -.37* .24 - - .05 -.09 .05 
  3 Month -.04 -.28 -.03 -.07 -.09 .14 .09 -.23 
  6 Month -.26 -.21 -.07 -.20 -.25 .30 .33* -.09 
*p < .05. **p < .01. ***p < .001. 
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 Table 10 
 
Correlations between background variables and SCL-90 Subscales (n = 42) 
 Marriage Income Psych Med Eating 
Habits 
Alcohol 
Use 
OCD      
  Diagnosis -.27 .03 .49** .01 -.05 
  3 Month -.30 -.01 .22 .22 .02 
  6 Month -.42** -.23 .23 .07 -.09 
Interpersonal      
  Diagnosis -.39* -.34* .32* .03 -.32* 
  3 Month -.44** -.30 .34* .31* -.26 
  6 Month -.55** -.48** .15 -.02 -.23 
Depression      
  Diagnosis -.23 .08 .43** -.04 -.08 
  3 Month -.26 -.08 .36* .14 -.16 
  6 Month -.41** -.30 .21 .17 -.22 
Anxiety      
  Diagnosis -.22 .10 .48** -.10 -.03 
  3 Month -.18 -.04 .34 .13 -.13 
  6 Month -.32* -.25 .21 .16 -.02 
Hostility      
  Diagnosis -.13 -.19 .36* -.09 -.39* 
  3 Month -.10 -.37* .17 -.02 -.06 
Table 10 (continued).  
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  6 Month -.24 -.37* .01 .05 -.01 
Paranoid      
  Diagnosis -.32* -.18 .32* .12 -.31 
  3 Month -.40** -.37* .23 .04 -.33* 
  6 Month -.42** .41* -.01 -.15 -.35* 
Psychotic      
  Diagnosis -.33* .17 .42** .03 -.16 
  3 Month -.43** -.28 .33* .27 -.20 
  6 Month -.42** -.36* .26 .02 -.24 
Phobia      
  Diagnosis -.19 -.13 .53** -.07 -.19 
  3 Month .33* -.26  .49** .10 -.25 
  6 Month .37* -.33* .42** .18 -.30 
*p < .05. **p < .01. ***p < .001. 
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 Table 11 
 
Correlations between medical variables and SCL-90 Subscales (n = 42) 
 BC 
Stage 
SBP Weight Chemo 
OCD     
  Diagnosis -.14 .15 .14 - 
  3 Month -.33* -.52** .29 -.13 
  6 Month -.25 .35 .24 -.22 
Interpersonal     
  Diagnosis -.40* .36 .43** - 
  3 Month -.25 .33 .29 -.15 
  6 Month -.24 .37 .35* -.34* 
Anxiety     
  Diagnosis -.13 .14 -.05 - 
  3 Month -.25 .37 .19 -.09 
  6 Month -.31* .40* .18 .32* 
Paranoid     
  Diagnosis -.28 .24 .21 - 
  3 Month   -.34* .15 .28 -.26 
  6 Month -.31* .31 .34* -.31* 
Psychotic     
  Diagnosis -.26 .28 .30 - 
  3 Month -.28 .37* .35* .15 
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 Table 11 (continued). 
 
  6 Month -.34* .30 .43* -.32* 
*p < .05. **p < .01. ***p < .001. 
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 A. Participant Statistics 
 
Sixty-five women were recruited for this study. A total of 58 women completed Time 1, 51 
women completed Time 2, and 42 completed Time 3. Differences between completers and 
noncompleters at each time point were analyzed using one-way analyses of variance (ANOVA) 
for continuous dependent variables and chi-squares for categorical dependent variables. There 
were no significant differences in Time 1 self-report measures between completers and 
noncompleters at Time 2 or 3. There were no differences between those who completed and 
those that did not at any time points on age, marriage, income, education, number of children at 
home, psychiatric medication use, family history of breast cancer history, or current breast 
cancer staging. Surgery type did not differentiate groups at Time 1 or Time 3, however, a 
difference emerged between surgery type and completion at Time 2 (χ2 = 11.4, p = .01), although 
due to small cell sizes this should be interpreted with caution. Table 12 contains a summary of 
these results. 
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 Table 12 
 
Completers and Non Completers at Time 2 Based on Surgery Type 
 
 
 Segmental 
Mastectomy 
Total 
Mastectomy 
Modified Radical 
Mastectomy 
Bilateral 
Mastectomy 
Completer 
(n = 50) 
42 (84%) 6 (12%) 2 (4%) 0 
Non Completer 
(n = 10) 
6 (60%) 2 (20%) 0 2(20%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 B. Aim 1  
 
The primary aim of this study was to evaluate the course of trait anxiety and acute symptoms of 
anxiety in patients newly diagnosed with breast cancer. It was expected that participants would 
report higher levels of acute anxiety at diagnosis than 3 or 6 months post-diagnosis. However, 
trait anxiety was not expected to decrease overtime from initial report. Furthermore, trait anxiety 
at diagnosis was expected to more strongly predict acute symptoms of anxiety overtime than was 
state anxiety at diagnosis.  
Only participants who completed all anxiety measures (i.e., STAI, DASS) at all time 
points were included in these analyses except where noted. Correlational analyses were 
conducted to examine the bivariate association between trait anxiety and acute anxiety over-time. 
As depicted in Table 13, the correlations between trait anxiety and acute anxiety (STAI and 
DASS) over time ranged from low to high (r = .14 and r = .73). In the first six months after 
breast cancer diagnosis, there was a clear pattern of bivariate association between trait anxiety 
and acute anxiety. Over time trait anxiety at diagnosis maintained a stronger correlational 
relationship with acute measures of anxiety than did state anxiety at diagnosis. 
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 Table 13 
 
Correlations of Trait and Acute Anxiety at Diagnosis with Acute Anxiety Over Time 
Anxiety variable Trait Anxiety at Diagnosis 
 Diagnosis 3 months 6 months 
State anxiety  .729*** .731*** .509** 
DASS anxiety  .639*** .454** .330* 
 State Anxiety at Diagnosis 
State anxiety   .662*** .454** 
DASS anxiety  .597*** .327* .135(NS) 
*p < .05. **p < .01. ***p < .001. 
 
 
 
Within subjects ANOVA analyses were done to examine changes in trait anxiety and acute 
anxiety over time. Pairwise analyses of means used paired observation t-tests coupled with a 
Bonferroni control for experiment wise error rates. Covariates were used in these analyses as 
indicated by the results of the bivariate correlations (Tables 5 and 6). Figure 1 shows the changes 
in trait and state anxiety over time. When examining trait anxiety changes over time, psychiatric 
medication use and cancer staging were used as covariates. As expected, there were no main 
time effects on trait anxiety F(2, 37) = .020, p = .980. There was a main effect of time on state 
anxiety F(2, 40) = 4.3, p = .020. State anxiety was significantly higher at diagnosis than 6-
months post-diagnosis (M = 6.0, SE = .18 and M = 5.5, SE = .13, respectively), F(1.67, 68.45) = 
6.50, p = .004.  When controlling for the use of psychiatric medication, there was no main effect 
40 
 of time on the DASS-A. Without this covariate, however, there was a main effect for time on the 
DASS-anxiety measure over time F(2, 40) = 3.2, p = .05. Pairwise comparisons did not reveal 
any statistically significant differences. This relationship is displayed in Figure 2. 
41 
  
0
5
10
15
20
25
30
35
40
1 2 3
Time
ST
A
I S
co
re
s
Trait
State
p =.015
 
Figure 1. Changes in state and trait anxiety from diagnosis to 3 and 6 months post diagnosis. 
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Figure 2. Changes in DASS-A from diagnosis to 3 and 6 months post diagnosis 
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 As depicted in Tables 14, 15, and 16, a series of regression equations were constructed to 
examine the predictive relationship between trait anxiety and acute anxiety in the first six months 
following breast cancer. Based on the zero-order correlations of variables among participants 
used in these analyses, psychiatric medication use, cancer staging, and marital status were 
controlled for as appropriate and are noted when used. To control for shared variance between 
the dependent variables, trait and state anxiety were simultaneously entered into all equations. 
Additionally, due to the moderate correlations between the measures of trait anxiety and acute 
anxiety and the associated problem of multicollinearity of the predictors the regression analyses 
were additionally run with each type of anxiety entered separately. Any differences between the 
analyses, with the variables entered together versus separately are noted. In addition to analyzing 
the results for the 42 full completers, when investigating the relationship between only Time1 
and Time 2 variables, analyses were run using participants that completed both Time 1 and Time 
2, but not Time 3 (n = 51).  
As shown in Table 14, when predicting anxiety 3 months after diagnosis, psychiatric 
medication use and cancer staging were controlled in all analyses. The regression equation was 
significant for predicting state anxiety 3-months post-diagnosis, accounting for 63% of the 
variance. Trait anxiety at diagnosis was the strongest predictor of state anxiety 3 months after 
diagnosis and cancer staging also significantly contributed to the model. The contribution of state 
anxiety at baseline and psychiatric medication were no more than expected by chance. When 
trait (β = .650, sr2 = .44, p < .001) and state anxiety (β = .555, sr2 = .39, p < .001) at diagnosis 
were entered separately, both were significant predictors of state anxiety 3 months post-
diagnosis. Although the regression equation was significant to predict DASS-A 3 months post-
diagnosis, none of the individual predictors reached statistical significance. When trait (β = .365, 
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 sr2 = .114, p = .035) and state anxiety (β = .227, sr2 = .056, p = .147) at diagnosis were entered 
separately, only trait anxiety was a significant predictor of DASS-A 3 months post-diagnosis. 
When entering all completers data in to the model, as shown in Table 15, trait anxiety at 
diagnosis was the strongest predictor of state anxiety 3 months after diagnosis, state anxiety and 
cancer staging also significantly contributed to the model. The contribution of psychiatric 
medication was no more than expected by chance. When trait (β = .640, sr2 = .45, p < .00) and 
state anxiety (β = .592, sr2 = .41, p < .00) at diagnosis were entered separately, both were 
significant predictors of state anxiety at 3 months post-diagnosis. The predictor model was 
significant to predict DASS-A 3 months post-diagnosis, although none of the individual 
predictors reached statistical significance. When trait (β = .402, sr2 = .16, p = .006) and state 
anxiety (β = .293, sr2 = .09, p = .041) at diagnosis were entered separately, both were significant 
predictors of DASS-A at 3 months post-diagnosis. 
When predicting anxiety 6-months post-diagnosis, based on bivariate correlation analyses, 
psychiatric medication use and marital status were controlled for in all analyses (Table 16). Six-
months post-diagnosis, the regression equation was significant in predicting state anxiety 
accounting for 33% of the variance. Neither type of anxiety at diagnosis uniquely significantly 
contributed to this equation. When trait (β = .515, sr2 = .21, p = .003) and state anxiety (β = .428, 
sr2 = .19, p = .004) at diagnosis were entered separately, both were significant predictors of state 
anxiety 6 months post-diagnosis. The regression equation did not significantly predict DASS-A 6 
months post-diagnosis. When entered separately, neither trait nor state anxiety at diagnosis 
significantly predicted DASS-anxiety 6-months post-diagnosis. 
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 Table 14 
 
Regressions Predicting Anxiety at 3 months for completers of all time points (n = 42) 
Variable β sr2 p 
STAI-Statea    
    Trait Anxiety at Diagnosis .417 .14 .021 
     State Anxiety at Diagnosis .285 .08 ns 
     Psychiatric Medication Use  .082 .01 ns 
     Cancer Staging -.246 .13 .026 
DASS Anxietyb    
    Trait Anxiety at Diagnosis .380 .06 ns 
     State Anxiety at Diagnosis -.018 .00 ns 
     Psychiatric Medication Use at Diagnosis .127 .02 ns 
     Cancer Staging -.131 .02 ns 
aF(4,36) = 15.37 , p < .001, R2 = .63  
 bF(4,36) = 2.88 , p = .036, R2 = .24 
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 Table 15 
 
Regressions Predicting Anxiety at 6 months for all Time 1 and Time 2 Completers (n = 51) 
Variable β sr2 p 
STAI-Statea    
    Trait Anxiety at Diagnosis .411 .14 .009 
     State Anxiety at Diagnosis .298 .09 .048 
     Psychiatric Medication Use  .027 .00 ns 
     Cancer Staging -.263 .13 .011 
DASS Anxietyb    
    Trait Anxiety at Diagnosis .393 .07 ns 
     State Anxiety at Diagnosis .012 .00 ns 
     Psychiatric Medication Use at Diagnosis .019 .00 ns 
     Cancer Staging -.164 .06 ns 
aF(4,44) = 16.14 , p < .001, R2 = .60  
bF(4,44) = 3.16, p = .023, R2 = .22 
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 Table 16 
 
Regressions Predicting Anxiety 6 months post diagnosis (n = 42) 
Variable β sr2 p 
STAI-Statea    
    Trait Anxiety at Diagnosis .326 .05 ns 
     State Anxiety at Diagnosis .218 .03 ns 
     Psychiatric Medication Use  -.088 .01 ns 
     Marital Status -.222 .06 ns 
DASS Anxietyb    
    Trait Anxiety at Diagnosis .415 .06 ns 
     State Anxiety at Diagnosis -.199 .02 ns 
     Psychiatric Medication Use  .122 .01 ns 
     Marital Status -.015 .00 ns 
aF(4,37) = 4.55 , p = .004, R2 = .33 
 bF(4,37) = 1.58, p = .200 , R2 =.15 
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C. Aim 2  
 
The second aim of this study included evaluating the course of psychosocial distress and quality 
of life related to physical functioning in patients diagnosed with breast cancer. It was expected 
that levels of psychosocial distress around diagnosis would be increased when compared to 
levels 3 and 6 months post-diagnosis. Measures targeting general stress, depression, general and 
medical worry, quality of life, and symptom reporting were evaluated. Additionally, it was 
expected that trait anxiety at diagnosis would more strongly predict psychosocial distress 
overtime than would state anxiety at diagnosis. Quality of life due to physical functioning was 
expected to fluctuate during the first 6 months due to the course of cancer treatments.  
Only participants that completed all time points are included in these analyses. When 
evaluating the course of psychosocial distress and quality of life related to physical functioning, 
demographic and medical variables that were related to the outcome variable were used at 
covariates as indicated by bivariate correlations (Tables 5 –11) and each use is noted. Covariates 
were also included in the regression equations as they related to the predictor and outcome 
measures. Correlational analyses were conducted to examine the bivariate association between 
trait and state anxiety and the other distress dimensions over time. As depicted in Table 17, the 
correlations between trait and state anxiety and the dependent variables ranged from low to high 
overtime (r = .00 to r = .84). Trait anxiety at diagnosis, with few exceptions, more strongly 
correlated with other measures of distress at diagnosis and 3 and 6 months post-diagnosis. 
Within subjects ANOVA and multiple analysis of variance (MANOVA) analyses were done to 
examine changes in dimensions of psychosocial stress and quality of life due to physical 
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 functioning overtime in this population. Pairwise analyses of means used paired observation t-
tests coupled with a Bonferroni control for experiment wise error rates.  
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 Table 17. 
 
Correlations of Trait and State Anxiety at Diagnosis with Distress Overtime (N = 42). 
 Diagnosis 3 months 6 months 
 Trait State Trait State Trait State 
DASS Depression .84*** .80*** .53*** .48** .40** .31* 
DASS Stress .69*** .61*** .51*** .47** ns ns 
WDQ Medical .49** .45** ns ns ns ns 
WDQ Total .69*** .48** .63*** .42** .45** .34* 
   Finances .35* ns .34* ns ns ns 
   Work .56*** .56*** .60*** .50** .38* ns 
   Aimless Future .69*** .55*** .60*** .50** .47** .44** 
   LackConfidence .73*** .42** .57*** ns .53*** ns 
   Relationship .60*** .36* .60*** .36* .35* ns 
SCL GSI  .86*** .76*** .67*** .54*** .61*** .47** 
  Somatic .73*** .67*** .47** .47** .40*** .38* 
  Obsess Compulsive .78*** .70*** .56*** .43** .60*** .45** 
   Interpersonal .61*** .36* .66*** .47** .59*** .41** 
   Depression .80*** .79*** .58*** .49** .58*** .41** 
   Anxiety .74*** .74*** .59*** .48** .51*** .42** 
   Hostility .62*** .49** .48** .44** ns .34* 
   Phobia .71*** .61*** .69*** .49** .53*** .35* 
   Paranoid .50** ns .67*** .45** .50** .30* 
   Psychotic .79*** .66*** .64*** .51*** .57*** .37* 
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 MOS General Health .51** .45** .34* .37* .41** .41** 
MOS Mental Health .76*** .79*** .60*** .65*** .47** .43** 
   Physical Function .32* ns ns ns ns ns 
   Physical Role ns .34* ns ns ns ns 
   Body Pain ns ns ns ns ns ns 
   Vitality .62*** .70*** ns .32* .41** .33* 
   Social Function ns .36* ns ns ns ns 
   Emotional Role .48** .51*** ns ns ns ns 
   Health Transitions ns ns ns ns ns ns 
*p < .05. **p < .01. ***p < .001. 
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 When using psychiatric medication use as a covariate, there were no significant time 
effects on measures of depression. Without the use of this covariate, however, there was a main 
effect of time on depression as measured by the DASS F(2, 40) = 4.2, p = .022. Depression was 
significantly higher at diagnosis than 6-months post-diagnosis (M = 2.1, SE = .21 and M = 1.6, 
SE = .19, respectively), F(2,82) = 4.43, p = .015.  When examining stress over time, psychiatric 
medication use was used as a covariate. There was a main time effect for stress F(2, 39) = 4.48, p 
= .018. With stress being higher at diagnosis (M = 2.71, SE = .20) than at 3 or 6 months post-
diagnosis  (M = 2.20, SE = .21 and M = 2.26, SE = .19, respectively) F(2,80) = 4.03, p = .021. 
Figure 3 shows these relationships. 
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Figure 3. Changes from diagnosis to 3 and 6 months after diagnosis in depression and stress as 
measured by the DASS. aDepression changes are significant only without using psychiatric 
medication use as a covariate. 
 
 
 
 There was no main effect of time on total general worry with or without using marital 
status as a covariate. Additionally, when examining the subscales of the WDQ there were no 
time effects with (i.e., weight and marriage) or without the use of covariates. When using age as 
a covariate, there were no main effects of medical worry across time. When not controlling for 
age, there was a main time effect on medical specific worries F(2,40) = 9.36, p < .001. Medical 
worries were higher at diagnosis (M = 3.04, SE = .16) than at 3 or 6 months post-diagnosis  (M = 
2.60, SE = .15 and M = 2.46, SE = .14, respectively) F(2,82) = 11.42, p < .001. Figure 4 displays 
the across time patterns of worry. 
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Figure 4. General worry and medical worry from diagnosis to 3 and 6 months post diagnosis. 
There are no significant changes in general worry across time and only when not using age as a 
covariate are the changes in medical worry significant.
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      There was no main time effect with or without the use of covariates (i.e., psychiatric 
medication use and marital status) on general symptom reporting as measured by the SCL-90. 
However, when the subscales of this measure were entered into a MANOVA, there was a 
multivariate effect of time F(18, 18) = 2.81, p = .017. Marital status and psychiatric medication 
were used as covariates in this analysis. There was a univariate time effect on somatic report 
F(2,70) = 5.16, p = .008. Somatic report was lower at diagnosis (M = 1.21, SE = .03) than at 3- or 
6-months post-diagnosis (M = 1.26, SE = .03 and M = 1.26, SE = .03, respectively). The anxiety 
subscale also demonstrated a univariate time effect F(2,70) = 7.0, p = .004. Anxiety was higher 
at diagnosis (M = 1.24, SE = .04) than at 3 or 6 months post-diagnosis  (M = 1.13, SE = .03 and 
M = 1.11, SE = .03, respectively). SCL-90 univariate effects are displayed in Figure 5. 
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Figure 5. Changes in the SCL-90 subscales from diagnosis to 3 and 6 months post diagnosis.  
Anxiety and somatic scales are significantly changing from diagnosis to 3 months and 6 months.  
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 Without the use of the covariates there was additionally a univariate time effect on the 
psychotic scale F(2,38) = 8.01, p < .001. Psychotic symptom report was higher at diagnosis (M = 
1.15, SE = .03) than at 3 or 6 months post-diagnosis  (M = 1.10, SE = .02 and M = 1.09, SE = .02, 
respectively) F(2, 78) = 10.27, p < .001. There were no differences over time on the obsessive-
compulsive, interpersonal, depression, hostility, phobia, or paranoid scales of the SCL-90-R. 
There was a main time effect for general mental health as measured by the MOS F(2, 38) = 
7.49, p = .002. Consistent with the psychosocial measures, mental health distress was 
significantly higher at diagnosis than 6 months post-diagnosis  (M = 5.06, SE = .30 and M = 4.08, 
SE = .27, respectively) F(2,78) = 7.01, p = .001. There was no main time effect on the general 
health scale. MANOVA analyses revealed a multivariate time effect for the subscales of the 
MOS-SF F(14, 22) = 2.36, p < .035 . Family history of breast cancer, age, and frequency of 
alcohol use were used as covariates in this analysis. Univariate time effects were significant for 
physical functioning limitations F(2, 70) = 11.14, p < .001. Physical functioning limitations 
significantly increased from diagnosis to both 3 and 6 months post-diagnosis (p < .001). There 
was a univariate time effect for physical role limitations F(2, 70) = 4.13, p =.02. Physical role 
limitations significantly increased from diagnosis to 3 months post-diagnosis (p <. 001). There 
was a univariate time effect for body pain F(2, 70) = 3.72, p =.03, however, pairwise 
comparisons were not significant. There was also a univariate effect for emotional role 
limitations F(1.73, 60.55) = 4.02, p = .022, again, pairwise comparisons were not significant. 
Significant effects are represented in Figure 6 and 7. 
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Figure 6. Significant changes across time on scales of the MOS. All change patterns are 
significant, with general mental health significantly changing from diagnosis to 6 months post 
diagnosis. 
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Figure 7. Physical Functioning subscales of the MOS. All main effects are significant. 
Additionally, there was an effect of from diagnosis to 3 months in physical role limitations and 
an effect from diagnosis to 6 months for physical functioning limits. 
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 Lastly, regression analyses were used to test the hypothesis that trait anxiety at diagnosis 
would more strongly predict psychosocial distress over time than state anxiety. As depicted in 
Tables 18, 19, and 20, a series of regression equations were constructed to examine the 
predictive relationship between trait and state anxiety on other measures of psychosocial distress 
at and following a diagnosis of breast cancer. The same strategy as presented in Aim 1 was used 
to control for shared variance and address multicollinearity of the predictors in the regression 
equations. When predicting general stress 3 and 6 months post-diagnosis, psychiatric medication 
use and cancer staging were controlled for in the analyses. The regression equation was 
significant for predicting general stress 3-months post-diagnosis, accounting for 37% of the 
variance. None of the individual predictor variables significantly contributed to this model 
(Table 18). When trait (β = .403, sr2 = .16, p = .013) and state anxiety (β = .356, sr2 = .15, p = 
.014) at diagnosis were entered separately, both were significant predictors of general stress 3 
months post-diagnosis. When predicting general stress 6-months post-diagnosis, the regression 
equation was not significant (Table 18). Neither regression equation was significant when trait 
and state were entered separately. 
When predicting depression 3 and 6 months post-diagnosis, psychiatric medication use was 
controlled for in all analyses. The regression equation was significant for predicting depression 
3-months post-diagnosis, accounting for 32% of the variance. None of the individual predictor 
variables significantly contributed to this model (Table 18). When trait (β = .509, sr2 = .22, p = 
.002) and state anxiety (β = .442, sr2 = .20, p = .003) at diagnosis were entered separately, both 
were significant predictors of depression 3 months post-diagnosis. When predicting depression 
6-months post-diagnosis, the regression equation approached significance (Table 18). When trait 
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 (β = .471, sr2 = .18, p = .006) and state anxiety at diagnosis were entered separately, only the 
equation with trait anxiety was significant. 
When predicting general worry 3 and 6 months post-diagnosis, psychiatric medication and 
marital status were controlled for in all analyses. The regression equation was significant for 
predicting general worry 3 months post-diagnosis, accounting for 42% of the variance. Only trait 
anxiety was a unique predictor in this model, the other predictors accounted for no more of the 
variance than expected by chance (Table 19). When trait (β = .598, sr2 = .31, p < .001) and state 
anxiety (β = .362, sr2 = .15, p = .014) at diagnosis were entered separately, both were significant 
predictors of general worry 3 months post-diagnosis. When predicting general worry 6-months 
post-diagnosis, the regression equation was again significant accounting for 32% of the variance 
(Table 19). In this equation, only marital status was a significant and unique predictor. When 
trait (β = .401, sr2 = .11, p = .017) and state anxiety (β = .308, sr2 = .11, p = .034) at diagnosis 
were entered separately, both were significant predictors of general worry six months post-
diagnosis. 
When predicting medical worry 3 and 6 months post-diagnosis, psychiatric medication and 
age were controlled for in all analyses. The regression equation did not significantly predict 
medical worry 3 months post-diagnosis. When trait (β = .354, sr2 = .11, p < .038) and state 
anxiety at diagnosis were entered separately to predict medical worry at 3 months, only the 
model including trait anxiety significantly predicted medical worry 3 months post-diagnosis. The 
regression equation did, however, significantly predict medical worry 6 months post-diagnosis 
accounting for 33% of the variance. Trait anxiety, psychological medication use, and age were 
significant predictors of medical worry. The contribution of state anxiety was no more than 
expected by chance. (Table 19). When trait (β = .350, sr2 = .12, p = .029) and state anxiety at 
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 diagnosis were entered separately into equations, both equations were significant, with trait 
anxiety at diagnosis significantly contributing to its equation while state anxiety at diagnosis did 
not.  
When predicting symptom reporting 3 and 6 months post-diagnosis, psychiatric medication 
and marital status were controlled for in all analyses. The regression equation was significant for 
predicting symptom reporting 3 months post-diagnosis, accounting for 49% of the variance. Only 
trait anxiety was a unique predictor in this model, the other predictors accounted for no more of 
the variance than expected by chance (Table 20). When trait (β = .607, sr2 = .34, p < .001) and 
state anxiety (β = .480, sr2 = .28, p = .001) at diagnosis were entered separately, both were 
significant predictors of symptom reporting 3 months post-diagnosis. When predicting symptom 
reporting 6-months post-diagnosis, the regression equation was again significant accounting for 
46% of the variance (Table 20). Trait anxiety and marital status were significant individual 
predictors of symptom reporting. When trait (β = .600, sr2 = .32, p < .001) and state anxiety (β = 
.431, sr2 = .22, p = .003) at diagnosis were entered separately, both were significant predictors of 
symptom reporting 6 months post-diagnosis. 
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 Table 18 
 
Regressions Predicting Dimensions of Distress 3 and 6 months post diagnosis (n = 42) 
Variable β sr2 p 
DASS Stress 3 monthsa    
    Trait Anxiety at Diagnosis .238 .03 ns 
     State Anxiety at Diagnosis .202 .02 ns 
     Psychiatric Medication Use  .167 .03 ns 
     Cancer Staging -.247 .08 ns 
DASS Stress 6 monthsb    
    Trait Anxiety at Diagnosis .020 .00 ns 
     State Anxiety at Diagnosis .189 .02 ns 
     Psychiatric Medication Use  .163 .02 ns 
     Cancer Staging -.225 .05 ns 
DASS Depression 3 monthsc    
    Trait Anxiety at Diagnosis .331 .07 ns 
     State Anxiety at Diagnosis .222 .03 ns 
     Psychiatric Medication Use at Diagnosis .098 .01 ns 
DASS Depression 6 monthsd    
    Trait Anxiety at Diagnosis .470 .09 .06 
     State Anxiety at Diagnosis .001 .00 ns 
     Psychiatric Medication Use at Diagnosis -.138 .02 ns 
aF(4,36) = 5.28 , p = .002, R2 = .37 bF(4,36) = 1.74, p = .163, R2 = .16 
cF(3, 38) = 5.82, p = .002, R2 = .32 dF(3, 38) = 2.81, p = .052, R2 = .18 
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 Table 19.  
 
Regressions Predicting Dimensions of Worry 3 and 6 months post diagnosis (n = 42) 
Variable β sr2 p 
General Worry 3 monthsa    
    Trait Anxiety at Diagnosis .643 .18 .006 
     State Anxiety at Diagnosis -.053 .00 ns 
     Psychiatric Medication Use  -.031 .00 ns 
     Marital Status -.145 .03 ns 
General Worry 6 monthsb    
    Trait Anxiety at Diagnosis .303 .04 ns 
     State Anxiety at Diagnosis .112 .01 ns 
     Psychiatric Medication Use  -.073 .01 ns 
     Marital Status -.343 .12 .03 
Medical Worry 3 monthsc    
    Trait Anxiety at Diagnosis .482 .08 ns 
     State Anxiety at Diagnosis -.149 .01 ns 
     Psychiatric Medication Use  -.215 .04 ns 
     Age -.424 .15 .016 
Medical Worry 6 monthsd    
    Trait Anxiety at Diagnosis .590 .14 .02 
     State Anxiety at Diagnosis -.281 .04 ns 
     Psychiatric Medication Use  -.376 .12 .03 
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 Table 19 (continued). 
     Age -.595 .28 .00 
aF(4, 37) = 6.82, p < .001, R2 = .42 bF(4, 37) = 4.35, p = .006, R2 = .32 
 
cF(4, 37) = 2.47, p = .062, R2 = .21  dF(4, 37) = 4.51, p = .005, R2 = .32  
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Table 20 
 
Regressions Predicting Symptom Reporting 3 and 6 months post diagnosis (n = 42) 
Variable β sr2 p 
Symptom Reporting  3 monthsa    
    Trait Anxiety at Diagnosis .434 .11 .04 
     State Anxiety at Diagnosis .201 .03 ns 
     Psychiatric Medication Use  .095 .01 ns 
     Marital Status -.190 .06 ns 
Symptom Reporting 6 monthsb    
    Trait Anxiety at Diagnosis .513 .13 .02 
     State Anxiety at Diagnosis .100 .01 ns 
     Psychiatric Medication Use  -.100 .01 ns 
     Marital Status -.262 .10 .06 
aF(4, 36) = 8.79, p < .001, R2 = .49 
bF(4, 36) = 7.61, p < .001, R2 = .46 
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D. Aim 3  
 
The final aim of this study was to explore the course of the relationship between physiological 
measures of anxiety and self-report measures of anxiety. First, it was expected that increased 
levels of physiological stress as measured by salivary cortisol would be related to self-report 
measures of anxiety at each time point. It was also expected that salivary cortisol levels at 
diagnosis would account for a significant amount of the variance in self-reported anxiety at 
diagnosis, 3- and 6-months post-diagnosis. The ability of self-report anxiety and physiological 
measures of anxiety at diagnosis to predict anxiety at 3 and 6 months post-diagnosis was 
explored.  
Cortisol levels at each time point were calculated using an “area under the curve with 
respect to increase” formula (Pruessner, Kirshbaum, Meinlschmid, & Hellhammer, 2003). This 
measurement method disregards the distance from zero for all measurements, and emphasizes 
the changes over time, with greater decrease during the course of the day suggesting lower 
overall levels of cortisol. Past research has found this measurement formula to be more reflective 
of psychological stress than other commonly used formulas (Pruessner et al., 2003).  
Participants that completed all questionnaires and cortisol measurements at any time point 
are included in these analyses. At diagnosis there were 38 participants that met these criteria, at 3 
and 6 months post-diagnosis there were 29 and 24 respectively. In addition to cortisol 
measurements the core anxiety measures for this study (i.e., STAI, DASS-A) were used in these 
analyses. One-way ANOVAs and chi-squares tests were done to evaluate differences on 
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 background variables or self-report measures among participants that did and did not have 
available cortisol data. At diagnosis and 6 months, there were no significant differences in these 
variables. At 3 months, none of the 4 participants that reported currently smoking had available 
cortisol data (22 total without cortisol data), while none of the 29 participants with cortisol data 
were smokers (χ2 = .5.72, p = .017). Due to small cell sizes this statistic should be considered 
exploratory.  
Correlational analyses were conducted to examine the association between cortisol levels 
and self-report anxiety measures and all background, health behaviors, and medical variables. 
There were only two significant relationships that emerged. At 3 months the use of psychiatric 
medication (n = 3) was negatively correlated with cortisol levels (r = .398, p = .032) and at 6 
months cortisol levels were related to menopausal status (r = -.538, p = .012). Correlations were 
rerun excluding the three participants on medication, no differences were found. Among the 
anxiety self-reports, as expected, there was a relationship between DASS-A at diagnosis and 
cortisol measurement at diagnosis (r = .422, p = .008). However, no other relationships were 
significant. Due to the low number of participants who completed cortisol measurements at all 
three time points (n = 16), dependent T-tests were used to compare differences between each 
time point thus increasing the number of data points for each test. The results of these tests were 
not significant; no differences in cortisol measurements were seen between time points.  
Based on the results of the bivariate correlations, a regression model was constructed to 
examine the predictive relationship of cortisol to DASS-A (Table 21). Initial correlations (Table 
13) revealed that DASS-A at diagnosis and 3 months was related to both state and trait anxiety at 
diagnosis. For this reason, these two factors were also included in the regression equations. The 
results of the regression equation for predicting DASS-A at diagnosis were significant (Table 
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 21). This equation accounted for 58% of the variance in DASS-A and trait anxiety and cortisol 
significantly contributed to the model. The contribution of state anxiety was no more than 
expected by chance. These variables were not significant in predicting anxiety at 3 months. 
However, anxiety variables at diagnosis did significantly predict anxiety 6 months post-diagnosis 
accounting for 26% of the variance in anxiety 6 months post-diagnosis. 
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 Table 21 
 
Regressions Predicting Anxiety with Cortisol (n = 38) 
Variable β sr2 p 
DASS Anxiety at Diagnosisa    
    Trait Anxiety at Diagnosis .590 .26 .002 
    State Anxiety at Diagnosis .064 .00 ns 
   Cortisol at Diagnosis .353 .22 .003 
DASS Anxiety at 3 monthsb    
    Trait Anxiety at Diagnosis .255 .03 ns 
    State Anxiety at Diagnosis .204 .02 ns 
   Cortisol at Diagnosis .094 .01 ns 
DASS Anxiety at 6 monthsc    
    Trait Anxiety at Diagnosis .639 .26 .03 
    State Anxiety at Diagnosis -.265 .00 ns 
   Cortisol at Diagnosis .201 .22 ns 
aF(3,34) = 15.83 , p < .001, R2 = .58 
bF(3,32) = 2.71 , p = .061, R2 = .20 
cF(3,27) = 3.16 , p =.041, R2 = .26 
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IV. SUMMARY AND DISCUSSION 
 
 
This study focused on examining the impact of trait anxiety on distress overtime in patients with 
a new diagnosis of breast cancer. Specifically, this study differentiated between trait anxiety and 
acute anxiety symptom patterns. As expected, trait anxiety was stable in the first six months after 
the diagnosis of breast cancer, while acute measures of anxiety significantly decreased from 
diagnosis to 6-months after diagnosis. Consistent with research on stress reactions (Craig et al., 
1995), at diagnosis elevated levels of state anxiety may be a normal reaction to the diagnosis of a 
life threatening disease and could promote the use of resources to cope with the stressful event.  
A decline in state anxiety across time may be unique to populations of patients with early stage 
breast cancer; other studies with cancer patients with varying degrees of disease have found state 
anxiety levels to be more stable across time (Brewin et al., 1998). 
This study also investigated the course of other psychosocial distress in patients with a new 
diagnosis of breast cancer. As expected, measures of depression, stress, medical worry, and 
symptom reporting decreased from diagnosis to 6 months post-diagnosis. Measures of daily 
domains of general worry did not show a significant change from diagnosis to 6 months post-
diagnosis. This finding may suggest distress as a result of breast cancer diagnosis may be 
specific to the diagnosis and not globalize into other areas of functioning. Additionally, when 
controlling for age there was no longer a time effect on measures of medical worry. This finding 
suggests a unique interaction between age and medical worry. This finding is consistent with 
past research documenting age effects in this population. Compas et al. (1999) found that 
younger women experience increased distress compared to older women around the time of 
diagnosis, but that distress dissipates with time.  
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 When evaluating general symptom report (SCL-90), there was not a main effect across 
time. The anxiety subscale of this measures did, however, significantly decrease from diagnosis 
to six months after diagnosis, this is consistent with other acute anxiety measurements used in 
this study. The somatic subscale of the SCL-90 increased across time; this increase may be 
reflecting symptom reports that can be accounted for by the nature of cancer treatment. 
Differences in the direction of change on quality of life dimensions measured by the MOS 
(psychological distress decrease, physiological distress increase) also reflect this finding and are 
consistent with the initial unexpected stress of diagnosis and the subsequent course of physically 
challenging cancer treatment. Specifically, on the MOS, general mental health and emotional 
role limitations decreased over time, while limits in physical functioning, physical role, and 
limits due to body pain fluctuated during the course of the study.  
As would be expected, the use of psychiatric medication was consistently related to several 
of the distress outcome variables. The only psychosocial outcome measures that psychiatric 
medication use was not related to at any of the time points were state anxiety and worries related 
to medical domains. This unique lack of relationship with state anxiety may further suggest that 
state anxiety is reflecting a transient and normative reaction to the diagnosis of a life-threatening 
disease. Marital status was consistently negatively related to several of the psychosocial outcome 
variables. Past research has documented the benefits of social support in this population (Glanz 
& Lerman, 1992; Lewis et al., 2001; Trunzo & Pinto, 2003). The presence of a spouse may 
provide social support and account for decreased distress found here among married women. 
Unexpectedly, cancer staging and psychosocial distress were consistently negatively 
related. One possible hypothesis for this finding involves appraisal processes suggested in the 
stress response (Lazarus & Folkman, 1984). Although current medical treatment of early stage 
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 breast cancer is often successful for recovery, women continue to fear a diagnosis of breast 
cancer more than other diseases. When a woman is told that her early stage cancer is likely to be 
successfully treated, this information may be incongruent with what she believes causing 
feelings of low mastery over the situation and uncertainty. These constructs are known to 
produce avoidant coping strategies that lead to higher levels of distress (i.e., Sweet, Savoie, & 
Lemyre, 1999). However, when a woman is told that she has more severe breast cancer, she may 
appraise the situation as what she would expect from a diagnosis and be able to use coping 
strategies that decrease distress. This hypothesis would be best tested with a wider degree of 
disease status at diagnosis than is found in this study. 
 
A. Anxiety and Psychosocial Distress Across Time 
 
 
Overall, anxiety at diagnosis was related to poorer psychosocial outcomes during the first six 
months following a diagnosis of breast cancer. Both state and trait anxiety were correlated with 
increased psychosocial distress at diagnosis and at 3 and 6 months post-diagnosis. Regression 
analyses revealed that only trait anxiety at diagnosis was predictive of state anxiety 3 months 
post-diagnosis, although this relationship did not hold at six months. State anxiety at diagnosis 
was not uniquely predictive of state anxiety at either follow-up time point. These findings were 
somewhat modified when trait and state anxiety were entered into regression analyses separately 
to account for multicollinearity. Both types of anxiety were predictive of 3- and 6-month state 
anxiety, however, trait anxiety uniformly accounted for more of the variance in each equation.  
Regression equations predicting other measures of psychosocial distress revealed that trait 
anxiety was a unique predictor of general worry at 3 months, medical worry at 6 months, and 
general symptom reporting at 3 and 6 months. When findings were modified by entering trait and 
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 state anxiety into separate equations, on all measures trait anxiety predicted more variance in 
each equation model than did state anxiety. Most of these differences were modest, however, 
when trait anxiety was entered separately it was uniquely predictive of depression at 6 months 
post-diagnosis, and uniquely predicted medical worry at 3 and 6 months. 
These results provide additional information on specific anxiety patterns in women with a 
new diagnosis of breast cancer. Correlation analyses are consistent with past research (Bleiker et 
al., 2000; Schreier & Williams, 2004), in that trait and state anxiety at diagnosis are both related 
to distress at diagnosis and overtime. Although independently both trait and state anxiety at 
diagnosis were predictive of state anxiety at 3- and 6-months, when entered simultaneously into 
regression equations trait anxiety was the only unique predictor of state anxiety at anytime point. 
Likewise, trait and state anxiety were independently correlated with several of the other 
psychosocial distress measures, but when entered in the equation simultaneously, trait anxiety 
was consistently unique in accounting for variance in psychosocial outcome measures. 
Caution must be used when interpreting these results. Although the measurement and 
differentiation of trait and state anxiety is theoretically and clinically important, as has been 
documented in past research (Kendler & Kocovski, 2001), it is difficult to accurately measure 
and interpret these constructs. Trait and state anxiety were highly correlated with each other and 
when entered simultaneously into the regression equation they were competing for shared 
variance. Bearing these factors in mind, these results may suggest that trait anxiety as opposed to 
state anxiety may put an individual at risk for long-term distress. In this population state anxiety 
may be more reflective of acute distress and may be a normative reaction to a life threatening 
disease diagnosis and provide energy to access resources that will promote coping behavior in 
the individual.  
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 Research studies often fail to differentiate anxiety measures and do not report or account 
for trait effects on state measurements when using anxiety as a predictor or outcome measure 
(e.g., Epping-Jordan et al., 1998; Ozalp, Sarioglu, Tuncel, Aslan, & Kadiogullari, 2003). Epping-
Jordan and colleagues reported that acute anxiety and depression at the time of diagnosis of 
breast cancer did not predict these symptoms 3 months after diagnosis, but levels of anxiety at 3 
months did predict anxiety at 6 months. This may reflect the current hypothesis and finding that 
acute anxiety at diagnosis dissipates over time, explaining why there was no significant 
predictive relationship between baseline and 3 month anxiety levels. However, it may be that the 
high levels of anxiety at 3 months are more reflective of trait anxiety than state anxiety, thus 
being the reason 3-month anxiety is predicting 6-month anxiety. When measuring anxiety across 
time, anxiety that is uniquely state anxiety may decrease over time, but trait anxiety that is being 
reflected in measures of state anxiety may continue to be reflected in higher scores in state 
anxiety. Not accounting for this possibility could lead to interpretation of results and conclusions 
that are inconsistent with actual experience of distress.  
At the time of diagnosis, cortisol levels were significantly related only to DASS-A. No 
relationship was found between other measures of anxiety and cortisol. The DASS-A was 
designed specifically considering the overlap of depression and anxiety symptoms and excluded 
items that could reflect depression symptoms as well as symptoms of anxiety (Crawford & 
Henry, 2003). Therefore, the DASS-A may be a more pure measure of strictly anxiety 
symptoms, thus accounting for the unique relationship of cortisol with this measure and not with 
other measures of anxiety. Varying degrees of relationships between physiological stress markers 
and biological disease markers have been reported (Lueken & Compas, 2002), yet information 
about the influence of specific psychological processes on physiological stress markers is not 
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 well understood. The unique relationship between anxiety as measured by the DASS-A and 
cortisol at diagnosis provides additional information on the nature of these relationships. 
 
B. Limitations and Future Directions 
 
 
This research supports the main hypothesis suggesting that trait anxiety may be a unique 
construct that can predict long-term distress in patients with disease. While the findings 
presented here answer some questions, this research also raises several issues. One important 
issue is the differential outcomes among measures of the construct of anxiety. Appropriately 
evaluating and applying the measurement of anxiety to the hypothesis being tested and 
accurately reporting anxiety symptom patterns is an important consideration that should be more 
adequately addressed in research. This issue is not unique to medical populations, but is 
particularly important to consider in these populations where stress and anxiety have routinely, 
but broadly, been associated with disease variables.  
Trait anxiety may become more predictive of long-term distress and the effects of state 
anxiety may continue to dissipate over a more extended period of time. Future research may 
want to consider these variables over a longer time period. Additionally, considering the current 
findings, future research should work toward identification of unique aspects and correlates of 
trait anxiety so that it can be distinguished from state anxiety. This may allow for an early 
determinant variable of long-term distress in disease populations. Interpretation of these results 
should consider that the levels of distress in this sample may be lower than distress in this 
general population. When considering participation in this study, the most anxious women might 
have declined participation. Additionally, due to the type and early stage of cancer in this 
sample, these findings may not generalize to more severe disease populations. 
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